- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.04. | In Bay Area, Gilead cuts 149 positions and Roche's diagnostics division lays off 108 | ||
| 07.04. | CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition | ||
| 07.04. | Novo's Wegovy, J&J's Tremfya step up TV ad spending amid March Madness tournament | ||
| 07.04. | Viatris agrees to pay up to $335M to settle opioid claims | ||
| 07.04. | CDMO AmplifyBio closes doors amid tough market for early-stage cell and gene therapy development | ||
| 07.04. | Rhythm eyes label expansion after Imcivree helps patients with brain damage-related obesity lose weight | ||
| 07.04. | Art Garfunkel joins Sun Pharma to share how psoriasis drug Ilumya provided bridge over troubled water | ||
| 04.04. | 'SNL' star Kenan Thompson serves up a new campaign for Phathom's Voquezna | ||
| 04.04. | Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push | ||
| 04.04. | FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk: reports | ||
| 04.04. | Eli Lilly CEO on Trump's tariffs: 'It'll be hard to come back from here' | ||
| 04.04. | GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty | ||
| 04.04. | Fierce Pharma Asia-Pharma CEOs meet Xi Jinping; Trump's tariffs; BioNTech's bispecific data | ||
| 03.04. | Amid FDA tumult, agency misses decision deadline on Novavax's COVID shot | ||
| 03.04. | Novo's commercial strategy head hits the exit, prompting a slew of executive team shakeups | ||
| 03.04. | After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe | ||
| 03.04. | Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors | ||
| 03.04. | Nxera Pharma appoints AstraZeneca alum as inaugural commercial chief | ||
| 03.04. | FDA inspection operations face risk of further disruption amid mass HHS layoffs: report | ||
| 03.04. | Havas Health adds execs at nascent New York agency as Real Chemistry strengthens in Europe | ||
| 02.04. | With biosimilar competition looming, Roche takes a hit with failure of high-dose Ocrevus | ||
| 02.04. | For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty | ||
| 02.04. | Japan's Marubeni takes on Sumitomo's Asia pharma business to make new company in deal worth up to $480M | ||
| 02.04. | Amid uncertainty in the US, Boehringer Ingelheim projects 'slight' revenue increase for '25 | ||
| 02.04. | FDA taps insider Scott Steele to lead CBER on acting basis after Peter Marks departure |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .